Rangan Maitra

List of Publications by Year
in descending order

34	783	516710 16	526287 27
papers	citations	h-index	g-index

34	34	34	1167
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthesis and characterization of an orally bioavailable small molecule agonist of the apelin receptor. Bioorganic and Medicinal Chemistry, 2022, 66, 116789.	3.0	6
2	Aplnr knockout mice display sex-specific changes in conditioned fear. Behavioural Brain Research, 2021, 400, 113059.	2.2	2
3	Peripherally Selective CB1 Receptor Antagonist Improves Symptoms of Metabolic Syndrome in Mice. ACS Pharmacology and Translational Science, 2021, 4, 757-764.	4.9	9
4	Pyrazole Agonist of the Apelin Receptor Improves Symptoms of Metabolic Syndrome in Mice. Journal of Medicinal Chemistry, 2021, 64, 3006-3025.	6.4	7
5	â€œPhoto-Rimonabantâ€ Synthesis and Biological Evaluation of Novel Photoswitchable Molecules Derived from Rimonabant Lead to a Highly Selective and Nanomolar â€œCis-Onâ€•CB₁R Antagonist. ACS Chemical Neuroscience, 2021, 12, 1632-1647.	3.5	17
6	Evaluation of Amide Bioisosteres Leading to 1,2,3-Triazole Containing Compounds as GPR88 Agonists: Design, Synthesis, and Structureâ€“Activity Relationship Studies. Journal of Medicinal Chemistry, 2021, 64, 12397-12413.	6.4	19
7	Identification of potent pyrazole based APELIN receptor (APJ) agonists. Bioorganic and Medicinal Chemistry, 2020, 28, 115237.	3.0	13
8	Design, Synthesis, and Structureâ€“Activity Relationship Studies of (4-Alkoxyphenyl)glycinamides and Bioisosteric 1,3,4-Oxadiazoles as GPR88 Agonists. Journal of Medicinal Chemistry, 2020, 63, 14989-15012.	6.4	9
9	Behavioral assessment of rimonabant under acute and chronic conditions. Behavioural Brain Research, 2020, 390, 112697.	2.2	14
10	Functionalized 6-(piperidin-1-yl)-8,9-diphenyl purines as inverse agonists of the CB1 receptor â€“ SAR efforts towards selectivity and peripheralization. Bioorganic and Medicinal Chemistry, 2019, 27, 3632-3649.	3.0	2
11	Dual-Acting Cholinesteraseâ€“Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo. Journal of Medicinal Chemistry, 2019, 62, 9078-9102.	6.4	35
12	Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor. Journal of Medicinal Chemistry, 2019, 62, 6330-6345.	6.4	10
13	A patent update on cannabinoid receptor 1 antagonists (2015-2018). Expert Opinion on Therapeutic Patents, 2019, 29, 261-269.	5.0	18
14	Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor. Journal of Medicinal Chemistry, 2018, 61, 4370-4385.	6.4	30
15	Discovery of a Potent, Selective, and Brain-Penetrant Small Molecule that Activates the Orphan Receptor GPR88 and Reduces Alcohol Intake. Journal of Medicinal Chemistry, 2018, 61, 6748-6758.	6.4	28
16	Synthesis and pharmacological characterization of functionalized 6-piperazin-1-yl-purines as cannabinoid receptor 1 (CB1) inverse agonists. Bioorganic and Medicinal Chemistry, 2018, 26, 4518-4531.	3.0	5
17	Development and validation of a high-throughput calcium mobilization assay for the orphan receptor GPR88. Journal of Biomedical Science, 2017, 24, 23.	7.0	13
18	Metabolic Profiling of CB1 Neutral Antagonists. Methods in Enzymology, 2017, 593, 199-215.	1.0	12

#	Article	IF	Citations
19	Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain. Journal of Medicinal Chemistry, 2016, 59, 7525-7543.	6.4	53
20	Discovery of a novel small molecule agonist scaffold for the APJ receptor. Bioorganic and Medicinal Chemistry, 2016, 24, 3758-3770.	3.0	26
21	Pyrazole antagonists of the CB1 receptor with reduced brain penetration. Bioorganic and Medicinal Chemistry, 2016, 24, 1063-1070.	3.0	19
22	Regulation of the Apelinergic System and Its Potential in Cardiovascular Disease: Peptides and Small Molecules as Tools for Discovery. Journal of Medicinal Chemistry, 2015, 58, 7913-7927.	6.4	40
23	Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents. Bioorganic and Medicinal Chemistry, 2015, 23, 6379-6388.	3.0	14
24	Identifying structural determinants of potency for analogs of apelin-13: Integration of C-terminal truncation with structureâ€“activity. Bioorganic and Medicinal Chemistry, 2014, 22, 2992-2997.	3.0	27
25	Peripherally Selective Diphenyl Purine Antagonist of the CB1 Receptor. Journal of Medicinal Chemistry, 2013, 56, 8066-8072.	6.4	19
26	Decreased Maternal Plasma Apelin Concentrations in Preeclampsia. Hypertension in Pregnancy, 2012, 31, 398-404.	1.1	35
27	Diphenyl Purine Derivatives as Peripherally Selective Cannabinoid Receptor 1 Antagonists. Journal of Medicinal Chemistry, 2012, 55, 10022-10032.	6.4	31
28	Structural analogs of pyrazole and sulfonamide cannabinoids: Effects on acute food intake in mice. European Journal of Pharmacology, 2012, 695, 62-70.	3.5	11
29	Design and Synthesis of Cannabinoid Receptor 1 Antagonists for Peripheral Selectivity. Journal of Medicinal Chemistry, 2012, 55, 2820-2834.	6.4	57
30	Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5711-5714.	2.2	29
31	A Disease-Relevant High-Content Screening Assay to Identify Anti-Inflammatory Compounds for Use in Cystic Fibrosis. Journal of Biomolecular Screening, 2010, 15, 1204-1210.	2.6	9
32	Synthesis and Biological Evaluation of Bivalent Ligands for the Cannabinoid 1 Receptor. Journal of Medicinal Chemistry, 2010, 53, 7048-7060.	6.4	62
33	Inhibition of NFÎºB by the natural product Withaferin A in cellular models of Cystic Fibrosis inflammation. Journal of Inflammation, 2009, 6, 15.	3.4	92
34	Altered Biogenesis of Î”F508-CFTR Following Treatment with Doxorubicin. Cellular Physiology and Biochemistry, 2007, 20, 465-472.	1.6	10